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Summary: Three modifications of the Chem-1 determination of serum creatinine were tested. Two different
algorithms developed for compensating the interference of bilirubin were compared with the current one by
analysing bilirubin-enriched albumin solutions and 82 icteric serum samples. A number of known other
interfering substances were also tested.
The modification involving parallel bichromatic measurement plus bilirubin correction appeared to give the
best performance.
However, despite the improvements, the determination is not yet completely satisfactory.
Introduction
In a previous study we discussed the problems related
to the determination of creatinine in icteric specimens
(1). That study was undertaken because of doubt
concerning some of our Chem-1 results. We also men-
tioned the involvement of the Bayer^Technicon com-
pany, which manufactures the Chem-1 analyser. In
this article we present the results of performance stud-
ies of three modifications of the creatinine assay, two
of them being experimental. All methods are kinetic
Jaffe methods. The original, unmodified procedure is
based on incubation of the sample with picric acid
and initiation of the colour reaction with sodium
hydroxide; there is no mathematical correction algo-
rithm for bilirubin.
The modifications differ in two respects from this
procedure. First, the addition of picric acid and so-
dium hydroxide is reversed. Second, two different
bilirubin correction algorithms are applied, i. e. a se-
lective bichromatic correction algorithm, and a par-
allel bichromatic measurement with a bilirubin cor-
rection for icteric samples.




Creatinine, unconjugated bilirubin, glucose, -hydroxybutyric
acid, ascorbic acid and acetone were obtained from Merck
(Germany), conjugated bilirubin (ditaurate, di Na) from Por-
phyrin Products Inc. (Logan, Utah, U.S.A.) and human al-
bumin from Behring Werke (Germany).
The following drugs were obtained from the Department of
Pharmacy in our hospital:





Icteric serum samples were provided by various departments in~
our hospital. Only samples with a total bilirubin concentration
higher than 100 μπιοΐ/ΐ were used. They were stored at -80 °C
prior to analysis. Table 1 shows the frequency distribution of
the bilirubin concentrations. Cyclosporin-containing serum
samples were obtained from our transplantation unit. All cy-
closporin concentrations, as determined by radioimmunoassay,
were lower than 100 mg/1 which is considered to be therapeutic.
Methods
An HPLC-based method already described by us (2) was used
as the reference method.
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We applied the following creatinine modifications of the cre-
atinine assay to the Chem-1.
1. Version 1. This version is commercially available. The sample
is mixed with picric acid and incubated for 5 minutes, after
which sodium hydroxide is added to initiate the reaction.
The ΔΑ between 30 and 90 seconds is measured at 500 nm,
and is proportional to the creatinine concentration.
2. Version 2. This version is described by Levy et al. (3). It
differs from version 1 mainly in the reversal of the order of
addition of the reagents, and in the measuring and calcula-
tion principle. Absorbance is measured at 500 and 600 nm
after addition of sodium hydroxide to the sample. The values
reflect the bilirubin concentration, and if they exceed a
certain threshold, a ratio test is performed for correction of
the final result.
3. Version 3. Here the same chemistry is used as in version 2.
A parallel bichromatic absorbance measurement at 500 and
600 nm is performed. The bilirubin correction is based on
the difference between the absorbances at 500 and 600 nm
in the first flow cell.
For all modifications, the Chem-1 was calibrated with the
Setpoint Chem-1 Calibrator. The system specific value was
established for this calibrator with our HPLC method by run-
ning a sample on five consecutive days in triplicate. The slope
of the Chem-1 was adjusted to 1.0 and the intercept to Ο μηιοΐ/ΐ.
The interference study was performed according to the CER-
MAB schedule (4). A stock solution of drugs, metabolites,
haemoglobin and lipids (Intralipid®) in water was diluted with
human albumin solution (40 g/1) to give 5-7 dilutions. The
dilutions were chosen to give low, normal, therapeutic or ele-
vated levels.
Unconjugated and conjugated bilirubin were used in accor-
dance with 1. c. (5, 6).
Results
1. Bilirubin in vitro and in vivo
We started the study by comparing all three Chem-1
creatinine versions using bilirubin-enriched albumin
solutions. Three aqueous creatinine standard solu-
tions were compared, containing about 100, 300 and
500 μηιοΐ/ΐ. The results for 100 μιηοΐ/ΐ are shown in





Fig. 1. The influence of unconjugated bilirubin (added as bili-
rubin-enriched albumin solutions) on three Chem-1 cre-
atinine modifications:
D = version 1 = original version
+ = version 2 = modification Levy
* = version 3 = research version
The procedure was repeated using ditaurobilirubin-
enriched albumin solutions (2). The results can be
seen in figure 2.
From figures 1 and 2 it is clear that version 3 gives
the best performance, although a bilirubin effect can
still be measured. Nevertheless, it seemed worthwhile
to test the method modifications in the daily routine
by analysing icteric patient specimens. We therefore
analysed 82 icteric sera, with total bilirubin concen-
trations ranging from 104 to 570 μηαοΐ/ΐ (the distri-
bution is given in table 1), using all three versions of
the method. The results are presented graphically in





Fig. 2. The influence of ditaurobilirubin (added as ditaurobi-
lirubin-enriched albumin solutions) on three Chem-1
creatinine modifications:
α = version 1 = original version
+ = version 2 = modification Levy
* == version 3 = research version
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Fig. 3. Comparison of the Chem-1 version 1 creatinine for-
mulation (y-axis) and our HPLC-based reference
method (x-axis) with 82 icteric samples.
The line y = χ is also depicted.
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Fig. 4. Comparison of the Chem-1 version 2 creatinine for-
mulation (y-axis) and our HPLC-based reference
method (x-axis) with 82 icteric samples.
The line y = χ is also depicted.
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Fig. 5. Comparison of the Chem-1 version 3 creatinine for-
mulation (y-axis) and our HPLC-based reference
method (x-axis) with 82 icteric samples.
The line y = χ is also depicted.
Babiok and Passing statistics: y = 0.97x + 40; r = 0.98
It is clear that the in vivo results, like the in vitro
results, also showed improvements. On the other
hand, it is also obvious that the final goal of accept-
able accuracy for all specimens is not attained by
version 3. This is best illustrated by the alternative
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Fig. 6. The difference in creatinine values between version 3
and HPLC (y-axis) plotted against the creatinine con-
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Fig. 7. The difference in creatinine values between version 3
and HPLC (y-axis) plotted against the bilirubin concen-
trations (x-axis) of the 82 icteric samples.
2. Other interferents in vitro
Bilirubin is not the only interfering substance in the
creatinine determination. Despite the efforts to im-
prove the Chem-1 creatinine methodology, we also
felt the need to test other well-known interfering com-
pounds. We therefore investigated the effects of hae-
moglobin, lipids, drugs (ascorbic acid, dopamine, do-
butamine and cephalosporins) and carbohydrate/lipid
metabolites (glucose, acetone and -hydroxybutyric
acid).
In all these studies we used the same system, i.e.
human albumin-based creatinine standards of about
100, 300 and 300 μιηοΐ/ΐ with increasing amounts of
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interferents. The tested concentrations of substances
that normally occur in vivo ranged from about normal
or zero values up to highly pathological. The tested
concentrations of drugs ranged from subtherapeutic
to severely elevated levels according to the informa-
tion sheets of the manufacturers of the drugs. A
survey of all the results is given in table 2.
Tab. 2. Some interference data on all Chem-1 creatinine mod-
ifications
















± = moderate influence
— = no influence
J) = see figures 1 and 2





































3) = moderate at glucose
40 mmol/1
4) = see figure 8
concentrations higher than
3. Cyclosporin in vivo
The effect of Cyclosporin was studied in vivo.
Figure 8 shows the results of the analyses with version
3 and by HPLC.
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Fig. 8. Comparison of the Chem-1 version 3 creatinine for-
mulation (y-axis) and our HPLC based reference
method (x-axis) with 66 cyclosporin-containing serum
samples.
The line y = χ is also depicted.
Bablok and Passing statistics: y = 0.94x + 41; r = 0.99
Discussion
For a better understanding it is helpful to show the
performance of version 3 with non-icteric, non-hae-
molytic and non-lipaemic samples. A graph is given
in figure 9.
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Fig. 9. Comparison of the Chern-1 version 3 creatinine for-
mulation (y-axis) and our HPLC-based reference
method (x-axis) with 36 non-icteric, non-haemolytic and
non-lipaemic serum samples.
The line y = χ is also depicted.
Bablok and Passing statistics: y = 0.96x + 62; r = 1.00
Versions 1 and 2 show comparable performances, and
their results are therefore not depicted.
The results shown in figure 9 are acceptable. The
same holds true for the precision of the measurement.
We found a coefficient of variation of 2.5% at 140
μηιοΐ/ΐ and 1.5% at 750 μπιοΐ/ΐ (10 days).
This study confirms our earlier findings (1), i.e. a
change in the reagent formulation and/or change in
the method of calculation can influence the results
substantially. In this respect, as can be seen from
figures 3, 4 and 5, version 3 shows the best perform-
ance with our set of samples. This is also obvious
from the standard error about the regression line (sy/x).
For version 1 we found an sy/x of 19.4 μπιοΐ/ΐ; the
corresponding values for versions 2 and 3 were 20.1
and 12.1 μιηοΐ/ΐ, respectively. The same range (0 — 500
μτηοΐ/ΐ) taken from the samples depicted in figure 9
(n = 23) gave an sy/x = 6.2 μτηοΐ/ΐ.
Comparison of figures 5 and 9 gives the impression
that the results obtained with icteric specimens ap-
proach those obtained with non-icteric specimens,
except that the first data show a larger scatter. This
raises the question, in relation to the bilirubin inter-
ference, of the limitation of the kinetic Jaffe procedure
as chosen by Bayer-Technicon: We wonder if there is
any more to be gained by further attempted improve-
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ment. Some "fine-tuning" is possible, as can be seen
from figure 7, and this is qualitatively confirmed by
the results shown in figures 1 and 2. Of course, care
has to be taken in comparing figures 1, 2 and 7
because of possible matrix effects (artificial samples
vs. patient samples). It is difficult to compare the new
findings with other comparable techniques. Based on
our own experience, partly described in our previous
publication, we feel that the results obtained with
icteric serum samples are not better and not worse
than those other techniques. Figure 5 probably shows
more or less the state of the art for a kinetic Jaffe
method.
The comparison of all graphs is somewhat masked
by our calibration of the Chem-1. Using the manu-
facturer's system-specific value of the Chem-1 cali-
brator and applying an intercept of 44 μπιοΐ/ΐ, also
stated by the manufacturer, the patient results are
assumed to be accurate. Since we had reason to ques-
tion this calibration system (7), we decided to establish
our own values (see Materials and Methods). This
resulted in a different calibrator value and a different
intercept and slope. It certainly means that the dif-
ferences between the measured results and the HPLC-
values (see for instance figures 6 and 7) are actually
less pronounced. It may also be worthwhile to inves-
tigate whether the matrix of the Chem-1 calibrator is
appropriate.
The various data also show that bilirubin is not the
only interferent. We checked the drug content of a
number of serum samples. Most of the information
thus obtained was difficult to interpret, because in all
cases the samples contained three or even more drugs.
On the other hand, the in vitro drug interference study
does not present a negative picture, although we are
aware that our choice was limited. For example, we
investigated the effects of three cephalosporins that
are widely used in our hospital, but more are availa-
ble. Of course, the ideal but also the most laborious
way of studying the influence of drugs is the in vivo
model that we used for the cyclosporins. It is clear
from figure 8 that version 3 performs well.
Taking all measurements and all consideration into
account, it is obvious that, despite the improvements
made, we cannot be completely satisfied with the
results, especially those in the lower and normal range.
There still is too much doubt concerning the accuracy
of values. We experienced most problems with critical
care patients (transplantation patients, neonates),
where a number, sometimes many, creatinine requests
were made over a relatively long period.
We think that version 3 can be followed by version 4
(fine-tuning of the bilirubin correction algorithm and
maybe an improved calibration procedure), but even
then there will be doubt because of other interferents.
We may need a completely different approach for
creatinine.
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